Pulmonary Drug Delivery Systems: Technologies and Global Markets

Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • April 2018 •
  • 121 pages •
  • Report ID: 715870 •
  • Format: PDF
Report Scope:
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.

In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type.This will include products approved by regulatory authorities in recent years.

Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.

A discussion of the major players is included in the Competitive Landscape section.The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements.

Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.

Report Includes:
- 74 tables
- A detailed overview and analysis of the global markets for pulmonary drug delivery systems
- Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
- A look at the regulatory environment, which has been a driving force in the healthcare industry
- Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
- Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd

Summary
Pulmonary drug delivery is an alternative to oral drug delivery.Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases due to systemic administration via fast absorption by the alveolar region.

The pulmonary drug delivery method depends on the development of simple, cost effective and easy to use devices.These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities.

Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance. The World Health Organization (WHO) estimates that there were approximately 251 million people
suffering from COPD globally in 2016. It is estimated by the WHO that nearly 3.17 million deaths occurred in 2015 due to the disease itself. The primary cause of the disease is smoking tobacco. The growing number of smokers in developing economies is increasing the incidence of the disease.

The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors that are driving the growth of themarket are the emergence of novel inhaler designs and increased use of non-invasive drug delivery methods.

The pulmonary drug delivery systems market is estimated at REDACTED in 2017, growing at acompound annual growth rate (CAGR) of REDACTED to reach REDACTED in 2022.